Marijn Gillissen Martijn Kedde Etsuko Yasuda Sophie Levie Arjen Bakker Yvonne Claassen Martino Bohne Dave Speijer Daisy Picavet Jan Stap Pauline van Helden Tim Beaumont Hergen Spits Mette Hazenberg. ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS.


Functional Cd47 Signal Regulatory Protein Alpha Sirpa Interaction Is Required For Optimal Human T And Natural Killer Nk Cell Homeostasis In Vivo Pnas

Search for more papers by this author.

Arjen bakker aimm therapeutics. The specific role of each author is articulated in the author contributions section. The commercial company AIMM therapeutics provided support in form of a small project fee. Loop is the open research network that increases the discoverability and impact of researchers and their work.

1040 am - 1055 am. 5 Dominique L. De Jong Immuno-Oncology Technology.

The discovery and characterization of broadly neutralizing antibodies bnAbs against influenza viruses have raised hopes for the development of monoclonal antibody mAb-based immunotherapy and the design of universal influenza vaccines. B Laboratory of Experimental Intensive Care and Anesthesiology Academic Medical Center University of Amsterdam 1105 AZ Amsterdam The Netherlands. Davide Corti Institute for Research in Biomedicine Switzerland Dissecting the Human B Cell Response to Pathogens and Self Antigens 1055 am - 1100 am.

HighlightsB cells play a role in graft-versus-leukaemia GvL responses after allogeneic haematopoietic cell transplantation. His responsibilities include strategic scientific leadership management of pre-clinical and clinical development and manufacturing business development support external collaboration and partnership management. AIMM Therapeutics and Academic Medical Center University of Amsterdam.

A AIMM Therapeutics 1105 BA Amsterdam The Netherlands. C Whitehead Institute for Biomedical Research Cambridge MA 02142. Because current AML treatment relies primarily on untargeted therapies with.

In addition to it co-authors from AIMM AB and KW were actively involved in experimental analysis and revision of the manuscript. Use Slintel to connect with top decision-makers at aimm therapeutics. By Hergen Spits Franka Couw enberg Arjen Q.

1100 am - 1230 pm. We recently described AT1413 an antibody produced by donor B cells of a patient with. AIMM Therapeutics and Academic Medical Center University of Amsterdam.

Bakker K ees W eijer. AACR Annual Meeting 2020. BAKKER ADRIANUS Q BEAUMONT TIM YASUDA Etsuko 2013-10-29 Publication of US8568726B2 publication Critical patentUS8568726B2en.

Kwakkenbos PhD Arjen Q. 2012-06-28 Assigned to AIMM THERAPEUTICS BV. Van Helden Julien.

Alexander Lex Berthold Hendrik Bakker PhD. In prospect of developing an oral dosage form of Infliximab for treatment of Crohns disease and rheumatoid arthritis freeze-drying vial vs Lyoguard trays and spray-drying were investigated as production method for stable powders. Dextran and inulin were used in combination with sucrose as stabilizing excipients.

Donor derived cytotoxic antibodies from transplanted AML patients targeting a cell surface expressed nuclear antigen. AIMM Therapeutics and 5 10 4 L cells. Cercel Gemma Moiset Arjen Q.

Acute myeloid leukemia AML is a high-risk disease with a poor prognosis particularly in elderly patients. April 27-28 2020 and June 22-24 2020. Acute myeloid leukemia AML is a high-risk disease with a poor prognosis particularly in elderly patients.

Allogeneic hematopoietic stem cell transplantation HSCT can cure acute myeloid leukemia AML when the donor immune system generates a potent graft versus leukemia GvL response. By Amsterdam UMC AIMM Therapeutics Amsterdam Infection G. MACSorted and FACSorted B cells were suspended in IMDM supplemented with 100 Uml penicillin 100 μgml streptomycin and 10 FBS all Fisher Scientific.

Reassignment AIMM THERAPEUTICS BV. Van Hal-van Veen Madalina G. 1 AIMM Therapeutics Academic Medical Center Meibergdreef 59 1105 BA Amsterdam The Netherlands.

Loop enables you to stay up-to-date with the latest discoveries and news connect with researchers and form new collaborations. 3 Abstract. Bakker PhD Hergen Spits PhD.

B-cells were then sorted by FACS and five PRRSV-specific B cells were isolated. All identified PRRSV-specific antibodies were found to be broadly binding to all PRRSV-2 isolates. 1AIMM Therapeutics Academic Medical Center Amsterdam The Netherlands 2Department of Cell Biology and Histology Academic Medical Center Amsterdam The Netherlands Find articles by Arjen Q.

Here we assessed the role of phagocytes in this process using human immune system HIS BALBc Rag2 IL-2Rγc mice in which human leukocytes are generated from transplanted hematopoietic progenitor cells. The aim of our study was to identify antibodies that are highly specific for AML and to discover novel tumor-specific antigens widely expressed on AML and MDS but not on healthy hematopoietic and non-hematopoietic cells. While the role of T cells and NK cells in GvL immune responses has been established the contribution of B cells to GvL responses is less clear.

Only one human bnAb CR8020 specifically recognizing group 2 influenza A viruses has been previously characterized that. The drying processes did not affect. CIMDM and plated 5 10 5 cellswell in a 24-well tissue culture plate containing 50 ngml final concentration recombinant murine IL-21 Fc fusion protein IL-21.

Van Geelen 1AIMM Therapeutics Academic Medical Center Amsterdam The Netherlands. Proprietary retroviral vector developed by AIMM Therapeutics containing genes highly expressed by germinal center B cells creating an immortalized B-cell population. Has served as our Chief Development Officer since October 2010.

D Department of Virology Central Veterinary Institute. Karolinska InstitutetKarolinska University Hospital Stockholm Sweden. The homeostatic control mechanisms regulating human leukocyte numbers are poorly understood.

Arjen BAKKER Senior Scientist Cited by 4209 Read 78 publications Contact Arjen BAKKER. Philadelphia PA Introduction CD43s a unique sialylated form of CD43 expressed by myeloid malignancies is a novel target and AT1413 an antibody targeting CD43s was shown to have therapeutic potential against acute myeloid leukemia AML and myelodysplastic syndrome. Because current AML treatment relies primarily on untargeted therapies with severe side effects that limit patient eligibility identification of novel therapeutic AML targets is highly desired.

Find useful insights on aimm therapeuticss employee technology stack location news alerts and more at Slintel. This makes them attractive but challenging targets for therapeutics. Novel therapeutic approaches such as immunotherapy directed against a specific tumor target are highly needed.

Arjen Bakker AIMM Therapeutics Antibody Engineering AIDed by Nature 1035 am - 1040 am.


Pin Op Aanbod Motor Occasions